EHA 2017 | Pembrolizumab: a promising agent for the treatment of MM

Nikhil Munshi

Nikhil Munshi, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, USA, discusses the use of pembrolizumab in treating multiple myeloma (MM), presented at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. As it has been observed that pembrolizumab may exert a synergistic therapeutic effect, studies involving the combination of pembrolizumab with other agents such as lenalidomide and pomalidomide have been evaluated and found to significantly improve response rates in MM patients, as explained by Dr. Munshi. From this, it appears that the future for pembrolizumab in the treatment of MM is promising.

Share this video  
Similar topics